In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease

Direct targeting of alpha-synuclein (ASYN) has emerged as a disease-modifying strategy for Parkinson’s disease and other synucleinopathies which is being approached using both small molecule compounds and ASYN-targeted biologics. Minzasolmin (UCB0599) is an orally bioavailable and brain-penetrant sm...

Descripción completa

Detalles Bibliográficos
Autores principales: Price, Diana L., Khan, Asma, Angers, Rachel, Cardenas, Alvaro, Prato, Maria Key, Bani, Massimo, Bonhaus, Douglas W., Citron, Martin, Biere, Anja-Leona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352257/
https://www.ncbi.nlm.nih.gov/pubmed/37460603
http://dx.doi.org/10.1038/s41531-023-00552-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352257/
https://www.ncbi.nlm.nih.gov/pubmed/37460603
http://dx.doi.org/10.1038/s41531-023-00552-7

Ejemplares similares